Format

Send to:

Choose Destination
See comment in PubMed Commons below
Curr Opin Investig Drugs. 2008 Mar;9(3):295-300.

11beta-hydroxysteroid dehydrogenase type 1 inhibitors for metabolic syndrome.

Author information

  • 1GlaxoSmithKline Pharmaceuticals, Department of Cardiac Biology, UW2510, Box 1539, 709 Swedeland Road, King of Prussia, PA 19406, USA. Christine.G.Schnackenberg@gsk.com

Abstract

The metabolic syndrome is a constellation of interrelated metabolic risk factors that appear to promote the development of diabetes and cardiovascular disease. These risk factors include abdominal obesity, insulin resistance, hypertension and dyslipidemia. 11beta-Hydroxysteroid dehydrogenase (11beta-HSD) catalyzes the interconversion of glucocorticoids through the activity of two isozymes: type 1 (11beta-HSD1) and type 2 (11beta-HSD2). 11beta-HSD1 converts inactive glucocorticoid to the active form, whereas 11beta-HSD2 converts active glucocorticoid to the inactive form. It is well established that reduced 11beta-HSD2 activity causes hypertension and electrolyte abnormalities. More recently, the pathophysiological role of 11beta-HSD1 has been explored and studies suggest that increased 11beta-HSD1 activity within target tissues may promote insulin resistance, obesity, hypertension and dyslipidemia. This review will discuss the evidence that inhibition of 11beta-HSD1 may be therapeutic in the treatment of the metabolic syndrome.

PMID:
18311666
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk